Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

被引：0
|
作者：
Franken, Mira D. [1 ]
Koopman, Miriam [1 ]
van Oijen, Martijn G. H. [2 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2016年 / 39卷 / 02期
关键词：
D O I：
10.1097/COC.0000000000000253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
    Davari, Majid
    Ashrafi, Farzaneh
    Maracy, Mohammadreza
    Aslani, Abolfazl
    Tabatabaei, Mohammadreza
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2015, 6
  • [43] Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
    Norum, J.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 532 - 537
  • [44] THE COST EFFECTIVENESS OF CETUXIMAB (ERBITUX) IN THE THIRD LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN THE UK
    Perard, R.
    Samyshkin, Y.
    Guillermin, A. L. G.
    VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [45] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
    Bokemeyer, Carsten
    Bondarenko, Igor
    Makhson, Anatoly
    Hartmann, Joerg T.
    Aparicio, Jorge
    de Braud, Filippo
    Donea, Serban
    Ludwig, Heinz
    Schuch, Gunter
    Stroh, Christopher
    Loos, Anja H.
    Zubel, Angela
    Koralewski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 663 - 671
  • [46] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [49] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [50] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
    Barroso, S.
    Sanches, E.
    Marques, Ferreira J.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito, Santo J.
    San-bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
12345